| Code | CSB-RA014679MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to andecaliximab, targeting matrix metalloproteinase-9 (MMP9), a zinc-dependent endopeptidase that plays a critical role in extracellular matrix remodeling and tissue restructuring. MMP9 degrades type IV and V collagens, gelatin, and other matrix components, making it essential for physiological processes including wound healing, angiogenesis, and tissue development. Dysregulated MMP9 activity is implicated in numerous pathological conditions, including cancer metastasis, inflammatory diseases, cardiovascular disorders, and fibrotic conditions where excessive matrix degradation contributes to disease progression.
Andecaliximab (GS-5745) is a humanized IgG4 monoclonal antibody that was developed to inhibit MMP9 activity and has been investigated in clinical trials for gastric cancer, ulcerative colitis, and fibrotic diseases. This biosimilar antibody provides researchers with a valuable tool for investigating MMP9-mediated pathways, exploring the enzyme's role in disease pathogenesis, and evaluating therapeutic strategies targeting matrix metalloproteinase activity in various experimental models and translational research settings.
There are currently no reviews for this product.